Holen Sie sich die Stockscreener-App
7.16
3.50%
-0.26
Handel nachbörslich:
7.30
0.14
+1.96%
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone - MSN
Rainbows and Unicorns: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Just Became A Lot More Optimistic - simplywall.st
Mersana Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Mersana Therapeutics price target adjusted to $36 at Truist after reverse split - MSN
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates - MSN
Truist Securities slashes Mersana stock price target to $36 from $250 - Investing.com Canada
Mersana Therapeutics Q2 2025 Earnings Preview - MSN
Guggenheim Downgrades Mersana Therapeutics to Buy, PT to $30 from $125. - AInvest
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call Transcript - Insider Monkey
Guggenheim lowers Mersana stock price target to $30 from $125 By Investing.com - Investing.com Canada
Mersana Therapeutics 2025 Q2 Earnings Slight EPS Improvement Amid Widening Net Loss - AInvest
Mersana Misses Fiscal Q2 Revenue Target - AOL.com
Mersana Therapeutics Inc. Bounces Off Moving Average SupportJuly 2025 Update & Expert Curated Trade Setups - beatles.ru
Mersana Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Mersana stock price target raised to $17 from $6 at BTIG - Investing.com Canada
Mersana Therapeutics (MRSN): Assessing the Path to Value Recovery Amid Clinical Progress and Financial Challenges - AInvest
Mersana Therapeutics Q2 2025: Unpacking Key Contradictions in Clinical Strategies and Patient Eligibility - AInvest
Mersana Therapeutics: Emi-Le Expansion Data Expected in H2 2025, $15M GSK Milestone Achieved - AInvest
Transcript : Mersana Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Mersana Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Mersana Therapeutics Q2 2025 Misses Revenue Forecast - Investing.com Australia
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Therapeutics Inc Reports Q2 2025 Earnings: EPS of -$3.93 and Revenue of $6.36 Million - GuruFocus
Mersana Therapeutics earnings missed by $4.71, revenue fell short of estimates - Investing.com Canada
Mersana Therapeutics Provides Business Update and Announces Seco - GuruFocus
Mersana Therapeutics Q2 2025 Financial Results and Business Update - TradingView
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results - GlobeNewswire
Mersana's Cancer Drug Trial Hits Major Enrollment Milestone, Reports $77M Cash Position - Stock Titan
What Technical Tools Say About Mersana Therapeutics Inc. RecoveryEntry Level Investment Outlook Review - beatles.ru
Can Traders Expect Breakout From Mersana Therapeutics Inc. This WeekStock Market Watch With Alerts Shows Unusual Activity - sundaytimes.kr
Mersana Therapeutics Inc. Uptrend in Early Stages Indicators Say YesInvestment Plan With Growth Optimization Finalized - beatles.ru
Mersana Therapeutics MRSN 2025Q2 Earnings Preview Upside Ahead on Promising Drug Pipeline - AInvest
Revenues Working Against Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Share Price Following 25% Dive - simplywall.st
Is Mersana Therapeutics Inc. still worth holding after the dipAI-Based Reversal Point Prediction Signal - Newser
Will Mersana Therapeutics Inc. outperform the marketPattern Recognition Tool for ROI Investors - Newser
Will Mersana Therapeutics Inc. stock go up soonBuy and Hold Strategy for Capital Safety - Newser
Mersana Therapeutics Inc expected to post a loss of $3.93 a shareEarnings Preview - TradingView
Mersana Therapeutics Inc.’s volatility index tracking explainedFree Entry Alert Based on Volume Spikes - Newser
Competitive Positioning of Mersana Therapeutics Inc.: Is It Leading or LaggingGrowth Watchlist for Long Term Positioning - Newser
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 | MRSN Stock News - GuruFocus
Mersana Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 - GlobeNewswire
Leading Cancer ADC Developer Mersana Therapeutics Reveals Q2 2025 Earnings Date: Pipeline Updates Expected - Stock Titan
Mersana Therapeutics (NASDAQ:MRSN) Cut to “Strong Sell” at Wall Street Zen - Defense World
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsTrading Volume Anomaly Summary and Insight - Newser
What are analysts’ price targets for Mersana Therapeutics Inc. in the next 12 monthsAchieve breakthrough gains with expert advice - Jammu Links News
Mersana Therapeutics Inc. Recovers — But Is It SustainableStock Portfolio Allocation Guidance for Volatile Markets - beatles.ru
Should I hold or sell Mersana Therapeutics Inc. stock in 2025Gain the edge with real-time market data - Jammu Links News
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionFree Stock Selection With High Accuracy - Newser
Does Mersana Therapeutics Inc. stock perform well during market downturnsExponential return rates - Jammu Links News
What are the latest earnings results for Mersana Therapeutics Inc.Invest confidently with professional guidance - Jammu Links News
How does Mersana Therapeutics Inc. generate profit in a changing economyRapidly expanding wealth - Jammu Links News
When is Mersana Therapeutics Inc. stock expected to show significant growthCapitalize on strong market momentum - Jammu Links News
How does Mersana Therapeutics Inc. compare to its industry peersGet timely alerts on top-performing stocks - Jammu Links News
Why is Mersana Therapeutics Inc. stock attracting strong analyst attentionRapid market gains - Jammu Links News
How volatile is Mersana Therapeutics Inc. stock compared to the marketIdentify winners with top-tier analysis - Jammu Links News
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):